王丽杰,郭其森.SLCO1B1基因多态性与伊立替康所致不良反应的关系[J].肿瘤学杂志,2015,21(5):432-435. |
SLCO1B1基因多态性与伊立替康所致不良反应的关系 |
The Relationship Between SLCO1B1 Gene Polymorphism and the Toxicities Caused by Irinotecan (CPT-11) |
投稿时间:2014-07-11 |
DOI:10.11735/j.issn.1671-170X.2015.05.B018 |
|
|
中文关键词: SLCO1B1基因 基因多态性 伊立替康 不良反应 |
英文关键词:SLCO1B1 gene gene polymorphism irinotecan(CPT?鄄11) toxicity |
基金项目: |
|
摘要点击次数: 2210 |
全文下载次数: 891 |
中文摘要: |
摘 要:伊立替康(CPT-11) 是一种临床应用广泛的抗肿瘤药物,但其可能发生的严重不良反应却常常影响它的临床使用。有关报道称,特异性分布于肝细胞基底膜外侧的有机阴离子转运蛋白1B1(OATP1B1)可显著影响CPT-11及其活性产物 SN-38的血药浓度,进而影响它的不良反应。文章就负责编码OATP1B1的编码基因SLCO1B1的基因多态性与CPT-11所致不良反应的关系作一综述。 |
英文摘要: |
Abstract:Irinotecan (CPT-11) is used widely for the treatment of patients with cancers. However,its possible serious toxicities often hinder its clinical use. Some studies have shown that organic anion transport protein 1B1(OATP1B1) distributed specifically in lateral region of basement membrane can significantly affect the serum drug concentration of CPT-11 and its active product SN-38,and also affect its toxicities .This paper reviews the relationship between the toxicities caused by CPT-11 and gene polymorphism of SLCO1B1 which takes charge of coding OATP1B1. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |